Avadel Pharmaceuticals (AVDL) Long-Term Deferred Tax (2016)
Historic Long-Term Deferred Tax for Avadel Pharmaceuticals (AVDL) over the last 5 years, with Q4 2016 value amounting to $10.3 million.
- Avadel Pharmaceuticals' Long-Term Deferred Tax fell 1069.86% to $10.3 million in Q4 2016 from the same period last year, while for Dec 2016 it was $10.3 million, marking a year-over-year decrease of 1069.86%. This contributed to the annual value of $10.3 million for FY2016, which is 1069.86% down from last year.
- As of Q4 2016, Avadel Pharmaceuticals' Long-Term Deferred Tax stood at $10.3 million, which was down 1069.86% from $11.2 million recorded in Q3 2016.
- Avadel Pharmaceuticals' 5-year Long-Term Deferred Tax high stood at $13.1 million for Q4 2014, and its period low was -$14.1 million during Q4 2012.
- Over the past 5 years, Avadel Pharmaceuticals' median Long-Term Deferred Tax value was $11.4 million (recorded in 2015), while the average stood at $7.6 million.
- Per our database at Business Quant, Avadel Pharmaceuticals' Long-Term Deferred Tax surged by 56692.8% in 2014 and then tumbled by 1160.89% in 2015.
- Over the past 5 years, Avadel Pharmaceuticals' Long-Term Deferred Tax (Quarter) stood at -$14.1 million in 2012, then surged by 80.14% to -$2.8 million in 2013, then soared by 566.93% to $13.1 million in 2014, then dropped by 11.61% to $11.6 million in 2015, then decreased by 10.7% to $10.3 million in 2016.
- Its Long-Term Deferred Tax stands at $10.3 million for Q4 2016, versus $11.2 million for Q3 2016 and $11.4 million for Q2 2016.